Methamphetamine-associated cardiomyopathy: an addiction medicine perspective.
addiction medicine
cardiomyopathy
heart failure
methamphetamine use disorder
methamphetamine-associated cardiomyopathy
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
30
06
2022
accepted:
22
09
2022
entrez:
24
1
2023
pubmed:
25
1
2023
medline:
27
1
2023
Statut:
ppublish
Résumé
Methamphetamine-associated cardiomyopathy (MaCM) is an increasingly recognised serious complication from methamphetamine (MA) use. It is characterised as the development of otherwise unexplained heart failure in the context of MA use. MaCM predominantly affects a young and vulnerable population with high morbidity and mortality. It is the second leading cause of mortality in patients with MA use disorder (MUD). Our understanding of MaCM pathogenesis is based on observational cohorts and autopsy studies. Currently, the treatment of MaCM is predicated on abstinence. Medical therapies offer some benefit to a minority of patients; however, without abstinence, medical therapies are often ineffective. Abstinence is difficult for most patients to achieve; all clinicians require an understanding of MaCM and how to educate patients on the risks of ongoing use. Where available, referral to addiction medicine specialists to assist with treatment of MUD is recommended. This review aims to: (i) explain the proposed pathologic mechanisms of MaCM; (ii) summarise recent recommendations of the screening and treatment of MaCM; and (iii) highlight the role of addiction medicine in the management of patient with MaCM.
Substances chimiques
Methamphetamine
44RAL3456C
Central Nervous System Stimulants
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-26Informations de copyright
© 2023 Royal Australasian College of Physicians.
Références
Australian Institute of Health and Welfare. National Drug Strategy Household Survey Detailed Report [Internet]. Canberra: Australian Institute of Health and Welfare; 2019 [cited 2022 31 May]. Available from URL: https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/summary.
Zhao SX, Deluna A, Kelsey K, Wang C, Swaminathan A, Staniec A et al. Socioeconomic burden of rising methamphetamine-associated heart failure hospitalizations in California from 2008 to 2018. Circ Cardiovasc Qual Outcomes 2021; 14: 788-800.
Darke S, Duflou J, Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: a national study. Drug Alc Depend 2017; 179: 174-9.
Schürer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R et al. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Fail 2017; 5: 435-45.
Sliman S, Waalen J, Shaw D. Methamphetamine-associated congestive heart failure: increasing prevalence and relationship of clinical outcomes to continued use or abstinence. Cardiovasc Toxicol 2016; 16: 381-9.
McKetin R, Sutherland R, Peacock A, Farrell M, Degenhardt L. Patterns of smoking and injecting methamphetamine and their association with health and social outcomes. Drug Alcohol Rev 2021; 40: 1256-65.
Sutherland R, Uporova J, Chandrasena U, Price O, Karlsson A, Gibbs D, et al. Australian Drug Trends 2021: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. 2021.
Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ. All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. Drug Alc Depend 2012; 125: 290-4.
Kalant H, Kalant OJ. Death in amphetamine users: causes and rates. Can Med Assoc J 1975; 112: 299-304.
Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal Methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol 2003; 41: 981-6.
Osekowski M, Trytell A, La Gerche A, Prior D, Macisaac A, Paratz ED. A comprehensive approach to managing methamphetamine-associated cardiomyopathy. Am J Cardiovasc Drugs 2022; 22: 385-93.
Won S, Hong RA, Shohet RV, Seto TB, Parikh NI. Methamphetamine-associated cardiomyopathy. Clin Cardiol 2013; 36: 737-42.
Thoi F, Scherer DJ, Kaye DM, Sanders P, Stokes MB. Methamphetamine-associated cardiomyopathy: addressing the clinical challenges. Heart Lung Circ 2022; 31: 616-22.
Orcholski ME, Khurshudyan A, Shamskhou EA, Yuan K, Chen IY, Kodani SD et al. Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2017; 313: L252-66.
Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK et al. Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol 2019; 39: 1739-46.
Reddy PKV, Ng TMH, Oh EE, Moady G, Elkayam U. Clinical characteristics and management of methamphetamine-associated cardiomyopathy: state-of-the-art review. J Am Heart Assoc 2020; 9 :1-11.
Voskoboinik A, Ihle JF, Bloom JE, Kaye DM. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J 2016; 46: 723-7.
Westover AN, Nakonezny PA, Haley RW. Acute myocardial infarction in young adults who abuse amphetamines. Drug Alcohol Dep 2008; 96: 49-56.
Paratz ED, Cunningham NJ, Macisaac AI. The cardiac complications of methamphetamines. Heart Lung Circ 2016; 25: 325-32.
AshaRani PV, Hombali A, Seow E, Ong WJ, Tan JH, Subramaniam M. Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alc Depend 2020; 212: 108060.
Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008; 27: 253-62.
Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML et al. 2021 ACC/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). Circ Cardiovasc Qual Outcomes 2021; 14: e000102.
Wearne TA, Cornish JL. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psych 2018; 9: 491.
Guerin AA, Bonomo Y, Lawrence AJ, Baune BT, Nestler EJ, Rossell SL et al. Cognition and related neural findings on methamphetamine use disorder: insights and treatment implications from schizophrenia research. Front Psych 2019; 10: 880.
Paratz ED, Zhao J, Sherwen AK, Scarlato R-M, Macisaac AI. Is an abnormal ECG just the tip of the ICE-berg? Examining the utility of electrocardiography in detecting methamphetamine-induced cardiac pathology. Heart Lung Circ 2017; 26: 684-9.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Bulimia nervosa among methamphetamine dependent adults: association with outcomes three years after treatment. Eat Disord 2011; 19: 259-69.
Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Rev Clin Pharmacol 2017; 10: 305-14.
Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med 2021; 384: 140-53.
Australian Institute of Health and Welfare. Alcohol, Tobacco & Other Drugs in Australia [Internet]. Canberra: Australian Institute of Health and Welfare; 2022 [cited 2022 31 May]. Available from URL: https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia.
OECD [homepage on the Internet] Paris: Organisation for Economic Co-operation and Development Health Statistics; 2021 [cited 2022 4 Apr]. Available from URL: https://www.oecd.org/australia/
Srisurapanont M, Sombatmai S, Boripuntakul T. Brief intervention for students with methamphetamine use disorders: a randomized controlled trial. Am J Addict 2007; 16: 111-6.
Aldridge A, Dowd W, Bray J. The relative impact of brief treatment versus brief intervention in primary health-care screening programs for substance use disorders. Addiction 2017; 112: 54-64.
Insight Centre For Alcohol and Other Drug Training and Workforce Development. Queensland Health. Meth Check: Ultra Brief Intervention Tool: Insight; 2022 [updated 03 Mar 2022; cited 2022 22 Jun]. Version 2. Available from: https://insight.qld.edu.au/shop/meth-check-ultra-brief-intervention-tool-insight-vers-20-2018
Peacock A, Uporova J, Karlsson A, Price O, Gibbs D, Swanton R, et al. Australian Drug Trends 2020: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. 2021.
Atkins J, Dopp AL, Temaner EB. Combatting the Stigma of Addiction - The Need for a Comprehensive Health System Approach. National Academy of Medicine, Washington, DC. NAM Perspectives; 2020.
Dore GJ. Elimination of hepatitis C in Australia by 2030: a decade and counting. Aust Prescr 2021; 44: 36-7.